Intervention not reported
Incidence of relapse (up to 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in incidence of relapse (up to 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐relapse mortality (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in non‐relapse mortality (at 36 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Graft failure (during study) · patients after allogeneic stem cell or bone marrow transplantation
The intervention showed no clear difference in graft failure (during study) (low certainty).
1 finding from 1 review
Intervention not reported
Adverse Events (during study) · patients after allogeneic stem cell or bone marrow transplantation
1 finding from 1 review
Overall survival at 5‐year · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Event‐free survival · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in event‐free survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Treatment‐related mortality · women with early poor prognosis breast cancer
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Second cancers at 4 ‐ 9‐year median · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Number of participants with at least 1 bleeding episode · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one bleeding episode compared with placebo (low certainty).
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one severe or life‐threatening… compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Proportion of patients receiving platelets · People with chronic bone marrow failure
Thrombopoietin mimetic probably leads to lower proportion of participants receiving a platelet transfusion compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion reaction · People with chronic bone marrow failure
1 finding from 1 review
Thromboembolism · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes thromboembolism compared with placebo (very low certainty).
1 finding from 1 review
Adverse drug reactions · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in drug reactions compared with placebo (low certainty).
1 finding from 1 review
Number of red cell transfusions per participant · People with chronic bone marrow failure
1 finding from 1 review
Self‐reported pain · children aged 2‐19 years with mixed medical (acute or chronic illness) or generally healthy undergoing venipuncture, immunization,…
1 finding from 1 review
Observer‐reported distress · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review
Behavioral measures‐ pain · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review
Behavioral measures‐ distress · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review